MX2013003561A - Composiciones y métodos para tratar la neoplasia. - Google Patents

Composiciones y métodos para tratar la neoplasia.

Info

Publication number
MX2013003561A
MX2013003561A MX2013003561A MX2013003561A MX2013003561A MX 2013003561 A MX2013003561 A MX 2013003561A MX 2013003561 A MX2013003561 A MX 2013003561A MX 2013003561 A MX2013003561 A MX 2013003561A MX 2013003561 A MX2013003561 A MX 2013003561A
Authority
MX
Mexico
Prior art keywords
antibody
seq
chimeric antibody
chimeric
cell
Prior art date
Application number
MX2013003561A
Other languages
English (en)
Spanish (es)
Inventor
Katerina Sidera
Avgi Mamalaki
Evangelia Patsavoudi
Original Assignee
Zestagen S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zestagen S A filed Critical Zestagen S A
Publication of MX2013003561A publication Critical patent/MX2013003561A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2013003561A 2010-09-27 2011-09-27 Composiciones y métodos para tratar la neoplasia. MX2013003561A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38676410P 2010-09-27 2010-09-27
PCT/EP2011/066791 WO2012041863A1 (en) 2010-09-27 2011-09-27 Compositions and methods for treating neoplasia

Publications (1)

Publication Number Publication Date
MX2013003561A true MX2013003561A (es) 2013-09-02

Family

ID=44675608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003561A MX2013003561A (es) 2010-09-27 2011-09-27 Composiciones y métodos para tratar la neoplasia.

Country Status (12)

Country Link
US (2) US9115192B2 (cg-RX-API-DMAC10.html)
EP (1) EP2621947A1 (cg-RX-API-DMAC10.html)
JP (1) JP5946459B2 (cg-RX-API-DMAC10.html)
KR (1) KR20140016240A (cg-RX-API-DMAC10.html)
CN (1) CN103459420B (cg-RX-API-DMAC10.html)
AU (1) AU2011310664B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013007327A2 (cg-RX-API-DMAC10.html)
CA (1) CA2812644A1 (cg-RX-API-DMAC10.html)
IL (1) IL225483A0 (cg-RX-API-DMAC10.html)
MX (1) MX2013003561A (cg-RX-API-DMAC10.html)
SG (1) SG189095A1 (cg-RX-API-DMAC10.html)
WO (1) WO2012041863A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI718086B (zh) 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
JP6488520B2 (ja) * 2013-08-20 2019-03-27 国立研究開発法人科学技術振興機構 ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
US10877024B2 (en) * 2015-05-12 2020-12-29 Superlab Far East Limited Methods of determining interferon having direct inhibitory effects on tumors and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
KR20070094890A (ko) * 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도

Also Published As

Publication number Publication date
BR112013007327A2 (pt) 2017-07-04
US20160075771A1 (en) 2016-03-17
US20130280244A1 (en) 2013-10-24
KR20140016240A (ko) 2014-02-07
SG189095A1 (en) 2013-05-31
IL225483A0 (en) 2013-06-27
CN103459420B (zh) 2016-09-28
CA2812644A1 (en) 2012-04-05
WO2012041863A1 (en) 2012-04-05
AU2011310664A1 (en) 2013-05-09
AU2011310664B2 (en) 2016-02-18
JP2013541944A (ja) 2013-11-21
US9115192B2 (en) 2015-08-25
JP5946459B2 (ja) 2016-07-06
CN103459420A (zh) 2013-12-18
EP2621947A1 (en) 2013-08-07
US9328161B2 (en) 2016-05-03

Similar Documents

Publication Publication Date Title
AU2011310664B2 (en) Compositions and methods for treating neoplasia
CN113544156B (zh) 抗Claudin18.2抗体及其应用
US10208125B2 (en) Anti-mucin 1 binding agents and uses thereof
US20200339692A1 (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CA2632094A1 (en) Carbonic anhydrase ix (g250) antibodies and methods of use thereof
JP7533897B2 (ja) 融合タンパク質およびその使用
CN102847148A (zh) 结合细胞内prl-1多肽或prl-3多肽的抗体
KR20150013935A (ko) 트랜스포터에 대한 항체 및 이의 용도
US20220153863A1 (en) Prame binding molecules and uses thereof
AU2024266887A1 (en) Epitope of regulatory T cell surface antigen and antibody specifically binding thereto
WO2008059616A1 (en) Antibody recognizing c-domain of midkine
JP5896568B2 (ja) 動脈硬化又は動脈硬化性疾患の治療剤、及び動脈硬化又は動脈硬化性疾患の診断薬
JP2018508206A (ja) Ｌ型電位開口型チャネルに対する抗体および関連方法
JP6535668B2 (ja) Ｂ細胞受容体複合体膜結合ＩｇＭを標的とする抗体およびその使用
US12624101B2 (en) Monoclonal antibodies against neonatal Nav1.5
HK40033721A (en) Anti-mucin 1 binding agents and uses thereof
EP4598961A1 (en) Glypican 3 antibody and related methods
HK40047979A (en) Fusion protein and use thereof
HK1226813A1 (en) Anti-mucin 1 binding agents and uses thereof
HK1226813B (en) Anti-mucin 1 binding agents and uses thereof
HK1181316B (en) Notch1 binding agents and methods of use thereof
HK1149483A1 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

Legal Events

Date Code Title Description
FA Abandonment or withdrawal